Search Results

QUALITROL IMMUNOASSAY PLUS CONTROL, Levels 1, 2 and 3, is a lyophilized QUAEFFROE immONessayed quality control material intended to monitor the naman ocrain bacoa a immunoassay test procedures that analyze performanoo of climos. Intreaputic drugs as listed in this package insert.

QUALITROL IMMUNOASSAY PLUS CONTROL, Levels 1, 2 and 3, is a lyophilized QUAEFFROE immONessayed quality control material

This looks like a 510(k) clearance letter from the FDA for a medical device called "QUALITROL IMMUNOASSAY PLUS CONTROL, Levels 1, 2 and 3." This letter grants market clearance based on substantial equivalence to a predicate device, rather than describing a study used for de novo approval or premarket approval (PMA) which would typically contain detailed acceptance criteria and study results.

Therefore, the provided document does not contain the information requested regarding acceptance criteria and a study proving the device meets those criteria. The letter confirms substantial equivalence but does not provide performance data or acceptance criteria for a new device.

Here's why the requested information cannot be extracted from this document:

• Type of Device: This is a quality control material for immunoassays, not a diagnostic or therapeutic device whose performance would be described in terms of sensitivity, specificity, accuracy, etc., in the same way.
• Regulatory Pathway: A 510(k) notification demonstrates substantial equivalence to a legally marketed predicate device. It typically relies on showing that the new device is as safe and effective as the predicate, often through comparisons of design, materials, and intended use, and sometimes through performance testing if necessary to demonstrate equivalence. It does not usually involve extensive clinical trials with pre-defined acceptance criteria for novel performance claims in the way a PMA or de novo submission would.
• Content of the Letter: The letter explicitly states, "We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices." It doesn't present a study or performance results.

To answer your questions, one would need to access the full 510(k) submission (K992939) which might contain summary performance data used to demonstrate substantial equivalence, but that information is not in this FDA clearance letter.

Ask a specific question about this device